Pathophysiological preconditions promoting mixed "black" pigment plus cholesterol gallstones in a ΔF508 mouse model of cystic fibrosis

American Journal of Physiology - Gastrointestinal and Liver Physiology

Volumn 299, Issue 1, 2010, Pages

  Freudenberg, Folke ^a,b   Leonard, Monika R ^b   Liu, Shou An ^b   Glickman, Jonathan N ^b   Carey, Martin C ^a,b  

^a HARVARD MEDICAL SCHOOL   (United States)

^b BRIGHAM AND WOMEN S HOSPITAL   (United States)

Author keywords

Bilirubin; Cystic fibrosis transmembrane conductance regulator; Enterohepatic cycling; Gallbladder; Hepatobiliary disease

Indexed keywords

BILE ACID; BILE SALT; BILIRUBIN; CALCIUM;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BILE COMPOSITION; C57BL 6 MOUSE; CHOLELITHIASIS; CHOLESTEROL STONE; CONTROLLED STUDY; CYSTIC FIBROSIS; ENTEROHEPATIC CIRCULATION; GALLSTONE FORMATION; HYDROPHOBICITY; MICROSCOPY; MORPHOLOGY; MOUSE; NONHUMAN; PATHOPHYSIOLOGY; PH; PHASE SEPARATION; PHYSICAL CHEMISTRY; PRIORITY JOURNAL;

ANIMALS; BILE; BILIRUBIN; CHOLELITHIASIS; CHOLESTEROL; CYSTIC FIBROSIS; DISEASE MODELS, ANIMAL; ENTEROHEPATIC CIRCULATION; FECES; FEMALE; GALLBLADDER; GALLSTONES; HYDROGEN-ION CONCENTRATION; HYDROPHOBICITY; MALE; MICE; MICE, INBRED CFTR; MUCINS; RISK FACTORS;

EID: 77954356636     PISSN: 01931857     EISSN: 15221547     Source Type: Journal    
DOI: 10.1152/ajpgi.00341.2009     Document Type: Article

References (68)

1. Angelico M, Gandin C, Canuzzi P, Bertasi S, Cantafora A, De Santis A, Quattrucci S, Antonelli M. Gallstones in cystic fibrosis: a critical reappraisal. Hepatology 14: 768-775, 1991.
2. Bartlett GR. Phosphorus assay in column chromatography. J Biol Chem 234: 466-468, 1959.
3. Bartlett JR, Friedman KJ, Ling SC, Pace RG, Bell SC, Bourke B, Castaldo G, Castellani C, Cipolli M, Colombo C, Colombo JL, Debray D, Fernandez A, Lacaille F, Macek M Jr, Rowland M, Salvatore F, Taylor CJ, Wainwright C, Wilschanski M, Zemkova D, Hannah WB, Phillips MJ, Corey M, Zielenski J, Dorfman R, Wang Y, Zou F, Silverman LM, Drumm ML, Wright FA, Lange EM, Durie PR, Knowles MR. Genetic modifiers of liver disease in cystic fibrosis. JAMA 302: 1076-1083, 2009.
4. Becker M, Staab D, Leiss O, von Bergmann K. Biliary lipid composition in patients with cystic fibrosis. J Pediatr Gastroenterol Nutr 8: 308-312, 1989.
5. Bijvelds MJ, Bronsveld I, Havinga R, Sinaasappel M, de Jonge HR, Verkade HJ. Fat absorption in cystic fibrosis mice is impeded by defective lipolysis and post-lipolytic events. Am J Physiol Gastrointest Liver Physiol 288: G646-G653, 2005.
6. Brink MA, Méndez-Sánchez N, Carey MC. Bilirubin cycles enterohepatically after ileal resection in the rat. Gastroenterology 110: 1945-1957, 1996.
7. Brink MA, Slors JF, Keulemans YC, Mok KS, De Waart DR, Carey MC, Groen AK, Tytgat GN. Enterohepatic cycling of bilirubin: a putative mechanism for pigment gallstone formation in ileal Crohn's disease. Gastroenterology 116: 1420-1427, 1999.
8. Brito MA, Silva RF, Brites D. Bilirubin induces loss of membrane lipids and exposure of phosphatidylserine in human erythrocytes. Cell Biol Toxicol 18: 181-192, 2002.
9. Cahalane MJ, Neubrand MW, Carey MC. Physical-chemical pathogenesis of pigment gallstones. Semin Liver Dis 8: 317-328, 1988.
10. Calligaris S, Cekic D, Roca-Burgos L, Gerin F, Mazzone G, Ostrow JD, Tiribelli C. Multidrug resistance associated protein 1 protects against bilirubin-induced cytotoxicity. FEBS Lett 580: 1355-1359, 2006.
11. Carey MC. Critical tables for calculating the cholesterol saturation of native bile. J Lipid Res 19: 945-955, 1978.
12. Carey MC, Ko G. The importance of total lipid concentration in determining cholesterol solubility in bile and the development of critical tables for calculating "percent cholesterol saturation" with a correction factor for ursodeoxycholate-rich bile. In: Biological Effects of Bile Acids, edited by Paumgartner G, Stiehl A, Gerok W. Lancaster, UK: MTP, 1979, p. 299-308.
13. Carey MC, Small DM. The physical chemistry of cholesterol solubility in bile. Relationship to gallstone formation and dissolution in man. J Clin Invest 61: 998-1026, 1978.
14. Carey MC, Spivak W. Physical chemistry of bile pigments and porphyrins with particular reference to bile. In: Bile Pigments and Jaundice. Molecular, Metabolic, and Medical Aspects, edited by Ostrow JD. New York: Dekker, 1986, p. 81-132.
15. Cesaratto L, Calligaris SD, Vascotto C, Deganuto M, Bellarosa C, Quadrifoglio F, Ostrow JD, Tiribelli C, Tell G. Bilirubin-induced cell toxicity involves PTEN activation through an APE1/Ref-1-dependent pathway. J Mol Med 85: 1099-1112, 2007.
16. Chaudry G, Navarro OM, Levine DS, Oudjhane K. Abdominal manifestations of cystic fibrosis in children. Pediatr Radiol 36: 233-240, 2006.
17. Chen Q, Amaral J, Biancani P, Behar J. Excess membrane cholesterol alters human gallbladder muscle contractility and membrane fluidity. Gastroenterology 116: 678-685, 1999.
18. Chinet T, Fouassier L, Dray-Charier N, Imam-Ghali M, Morel H, Mergey M, Dousset B, Parc R, Paul A, Housset C. Regulation of electrogenic anion secretion in normal and cystic fibrosis gallbladder mucosa. Hepatology 29: 5-13, 1999.
19. Cohen S, Kaplan M, Gottlieb L, Patterson J. Liver disease and gallstones in regional enteritis. Gastroenterology 60: 237-245, 1971.
20. Cohn JA, Strong TV, Picciotto MR, Nairn AC, Collins FS, Fitz JG. Localization of the cystic fibrosis transmembrane conductance regulator in human bile duct epithelial cells. Gastroenterology 105: 1857-1864, 1993.
21. Colombo C, Bertolini E, Assaisso ML, Bettinardi N, Giunta A, Podda M. Failure of ursodeoxycholic acid to dissolve radiolucent gallstones in patients with cystic fibrosis. Acta Paediatr 82: 562-565, 1993.
22. Corradini SG, Elisei W, Giovannelli L, Ripani C, Della Guardia P, Corsi A, Cantafora A, Capocaccia L, Ziparo V, Stipa V, Chirletti P, Caronna R, Lomanto D, Attili AF. Impaired human gallbladder lipid absorption in cholesterol gallstone disease and its effect on cholesterol solubility in bile. Gastroenterology 118: 912-920, 2000.
23. Couzin-Frankel J. Genetics. The promise of a cure: 20 years and counting. Science 324: 1504-1507, 2009.
24. Dawson PA, Haywood J, Craddock AL, Wilson M, Tietjen M, Kluckman K, Maeda N, Parks JS. Targeted deletion of the ileal bile acid transporter eliminates enterohepatic cycling of bile acids in mice. J Biol Chem 278: 33920-33927, 2003. (Pubitemid 37553226)
25. Delaney SJ, Alton EW, Smith SN, Lunn DP, Farley R, Lovelock PK, Thomson SA, Hume DA, Lamb D, Porteous DJ, Dorin JR, Wainwright BJ. Cystic fibrosis mice carrying the missense mutation G551D replicate human genotype-phenotype correlations. EMBO J 15: 955-963, 1996.
26. Erlinger S. Review article: new insights into the mechanisms of hepatic transport and bile secretion. J Gastroenterol Hepatol 11: 575-579, 1996. (Pubitemid 126734024)
27. Feranchak AP. Hepatobiliary complications of cystic fibrosis. Curr Gastroenterol Rep 6: 231-239, 2004.
28. Feranchak AP, Sokol RJ. Cholangiocyte biology and cystic fibrosis liver disease. Semin Liver Dis 21: 471-488, 2001. (Pubitemid 33131040)
29. French PJ, van Doorninck JH, Peters RH, Verbeek E, Ameen NA, Marino CR, de Jonge HR, Bijman J, Scholte BJ. A ΔF508 mutation in mouse cystic fibrosis transmembrane conductance regulator results in a temperature-sensitive processing defect in vivo. J Clin Invest 98: 1304-1312, 1996.
30. Freudenberg F, Broderick AL, Yu BB, Leonard MR, Glickman JN, Carey MC. Pathophysiological basis of liver disease in cystic fibrosis employing a ΔF508 mouse model. Am J Physiol Gastrointest Liver Physiol 294: G1411-G1420, 2008.
31. -/- mouse (Abstract). Gastroenterology 130: M1823, 2006.
32. Geier A, Wagner M, Dietrich CG, Trauner M. Principles of hepatic organic anion transporter regulation during cholestasis, inflammation and liver regeneration. Biochim Biophys Acta 1773: 283-308, 2007.
33. Grubb BR, Boucher RC. Pathophysiology of gene-targeted mouse models for cystic fibrosis. Physiol Rev 79: S193-S214, 1999.
34. Guilbault C, Saeed Z, Downey GP, Radzioch D. Cystic fibrosis mouse models. Am J Respir Cell Mol Biol 36: 1-7, 2007.
35. Hayden UL, Carey HV. Cellular localization of cystic fibrosis transmembrane regulator protein in piglet and mouse intestine. Cell Tissue Res 283: 209-213, 1996.
36. Heuman DM. Quantitative estimation of the hydrophilic-hydrophobic balance of mixed bile salt solutions. J Lipid Res 30: 719-730, 1989.
37. Ho KJ, Hsu SC, Chen JS, Ho LH. Human biliary -glucuronidase: correlation of its activity with deconjugation of bilirubin in the bile. Eur J Clin Invest 16: 361-367, 1986.
38. Ho YC, Ho KJ. Human β-glucuronidase. Measurement of its activity in gallbladder bile devoid of intrinsic interference. Dig Dis Sci 33: 435-442, 1988.
39. Ho YC, Ho LH, Ho KJ. Human hepatic β-glucuronidase: an enzyme kinetic study. Enzyme (Basel) 33: 9-17, 1985.
40. 3H]water. J Lipid Res 21: 364-376, 1980.
41. Khanuja B, Cheah YC, Hunt M, Nishina PM, Wang DQ, Chen HW, Billheimer JT, Carey MC, Paigen B. Lith1, a major gene affecting cholesterol gallstone formation among inbred strains of mice. Proc Natl Acad Sci USA 92: 7729-7733, 1995.
42. Kopelman H. Cystic fibrosis. 6. Gastrointestinal and nutritional aspects. Thorax 46: 261-267, 1991.
43. Lindblad A, Glaumann H, Strandvik B. Natural history of liver disease in cystic fibrosis. Hepatology 30: 1151-1158, 1999.
44. Lyons MA, Wittenburg H. Cholesterol gallstone susceptibility loci: a mouse map, candidate gene evaluation, and guide to human LITH genes. Gastroenterology 131: 1943-1970, 2006.
45. Maurer KJ, Rao VP, Ge Z, Rogers AB, Oura TJ, Carey MC, Fox JG. T-cell function is critical for murine cholesterol gallstone formation. Gastroenterology 133: 1304-1315, 2007.
46. 2+ electrode. Am J Physiol Gastrointest Liver Physiol 241: G182-G190, 1981.
47. ++ electrode. J Lab Clin Med 106: 611-618, 1985.
48. Nelson DL, Cox MM. Water. In: Lehninger Principles of Biochemistry (4th ed.), edited by Lehninger AL. New York: Freeman, 2004, p. 47-74.
49. O'Brien S, Mulcahy H, Fenlon H, O'Broin A, Casey M, Burke A, FitzGerald MX, Hegarty JE. Intestinal bile acid malabsorption in cystic fibrosis. Gut 34: 1137-1141, 1993.
50. Oppenheimer EH, Esterly JR. Hepatic changes in young infants with cystic fibrosis: possible relation to focal biliary cirrhosis. J Pediatr 86: 683-689, 1975.
51. Ostrow JD, Pascolo L, Brites D, Tiribelli C. Molecular basis of bilirubin-induced neurotoxicity. Trends Mol Med 10: 65-70, 2004.
52. Paigen B, Carey MC. Gallstones. In: The Genetic Basis of Common Diseases (2nd ed.), edited by King RA, Rotter JI, Motulsky AG. London: Oxford University Press, 2002, p. 298-335.
53. Portincasa P, Di Ciaula A, Baldassarre G, Palmieri V, Gentile A, Cimmino A, Palasciano G. Gallbladder motor function in gallstone patients: sonographic and in vitro studies on the role of gallstones, smooth muscle function and gallbladder wall inflammation. J Hepatol 21: 430-440, 1994.
54. Riordan JR, Rommens JM, Kerem B, Alon N, Rozmahel R, Grzelczak Z, Zielenski J, Lok S, Plavsic N, Chou JL, Drumm ML, Iannuzzi MC, Collins FS, Tsui LC. Identification of the cystic fibrosis gene: cloning and characterization of complementary DNA. Science 245: 1066-1073, 1989. (Pubitemid 19231814)
55. Rogers CS, Stoltz DA, Meyerholz DK, Ostedgaard LS, Rokhlina T, Taft PJ, Rogan MP, Pezzulo AA, Karp PH, Itani OA, Kabel AC, Wohlford-Lenane CL, Davis GJ, Hanfland RA, Smith TL, Samuel M, Wax D, Murphy CN, Rieke A, Whitworth K, Uc A, Starner TD, Brogden KA, Shilyansky J, McCray PB Jr, Zabner J, Prather RS, Welsh MJ. Disruption of the CFTR gene produces a model of cystic fibrosis in newborn pigs. Science 321: 1837-1841, 2008.
56. Rossi SS, Converse JL, Hofmann AF. High pressure liquid chromatographic analysis of conjugated bile acids in human bile: simultaneous resolution of sulfated and unsulfated lithocholyl amidates and the common conjugated bile acids. J Lipid Res 28: 589-595, 1987.
57. Rowe SM, Miller S, Sorscher EJ. Cystic fibrosis. N Engl J Med 352: 1992-2001, 2005.
58. Roy CC, Weber AM, Morin CL, Combes JC, Nussle D, Megevand A, Lasalle R. Abnormal biliary lipid composition in cystic fibrosis. Effect of pancreatic enzymes. N Engl J Med 297: 1301-1305, 1977.
59. Spivak W, Yuey W. Application of a rapid and efficient h.p.l.c. method to measure bilirubin and its conjugates from native bile and in model bile systems. Potential use as a tool for kinetic reactions and as an aid in diagnosis of hepatobiliary disease. Biochem J 234: 101-109, 1986.
60. Strandvik B, Einarsson K, Lindblad A, Angelin B. Bile acid kinetics and biliary lipid composition in cystic fibrosis. J Hepatol 25: 43-48, 1996.
61. Trotman BW, Bernstein SE, Bove KE, Wirt GD. Studies on the pathogenesis of pigment gallstones in hemolytic anemia: description and characteristics of a mouse model. J Clin Invest 65: 1301-1308, 1980.
62. Turley SD, Dietschy JM. Re-evaluation of the 3α-hydroxysteroid dehydrogenase assay for total bile acids in bile. J Lipid Res 19: 924-928, 1978.
63. Vercaemst R, Union A, Rosseneu M. Separation and quantitation of free cholesterol and cholesteryl esters in a macrophage cell line by highperformance liquid chromatography. J Chromatogr 494: 43-52, 1989. (Pubitemid 19250636)
64. Vítek L, Carey MC. Enterohepatic cycling of bilirubin as a cause of 'black' pigment gallstones in adult life. Eur J Clin Invest 33: 799-810, 2003.
65. Wang DQ, Afdhal NH. Genetic analysis of cholesterol gallstone formation: searching for Lith (gallstone) genes. Curr Gastroenterol Rep 6: 140-150, 2004.
66. Wang HH, Afdhal NH, Gendler SJ, Wang DQ. Evidence that gall-bladder epithelial mucin enhances cholesterol cholelithogenesis in MUC1 transgenic mice. Gastroenterology 131: 210-222, 2006.
67. Weber AM, Roy CC, Morin CL, Lasalle R. Malabsorption of bile acids in children with cystic fibrosis. N Engl J Med 289: 1001-1005, 1973.
68. Zeiher BG, Eichwald E, Zabner J, Smith JJ, Puga AP, McCray PB Jr, Capecchi MR, Welsh MJ, Thomas KR. A mouse model for the ΔF508 allele of cystic fibrosis. J Clin Invest 96: 2051-2064, 1995.